Advertisement

Prevalence and predictors of osteopenia and osteoporosis in patients with type 2 diabetes mellitus: a cross-sectional study from a tertiary care institute in North India

Abstract

Background

Patients with type 2 diabetes mellitus (T2DM) have an increased risk of hip and vertebral fractures. The increased fracture risk has largely been attributed to poor bone quality and microarchitecture. The contribution of bone quantity, measured as areal bone mineral density (BMD), to the risk of fracture is variable with most studies showing an increase in BMD in T2DM. The present study was undertaken to find out the prevalence of osteoporosis and osteopenia (based on BMD) in a cohort of patients with T2DM and delineate the possible modifiable and non-modifiable risk factors.

Methods

In this cross-sectional observational study, 252 otherwise ostensibly healthy patients with T2DM underwent dual energy X-ray absorptiometry (DEXA) scan. Osteoporosis and osteopenia were defined based on T-scores. The effect of modifiable and non-modifiable risk factors on BMD and osteoporosis were assessed.

Results

The mean age of the cohort was 59.9 years with a M:F ratio 2.9:3.4. The mean BMD at the lumbar spine and hip were 0.892 g/cm2 and 0.715 g/cm2, respectively. Males had significantly higher BMD at both the sites compared to females. The prevalence of osteoporosis and osteopenia was 33% and 40%, respectively. Female gender, increasing age, normal body mass index (BMI), low serum 25-hydroxyvitamin D, and use of pioglitazone were significantly associated with the risk of osteoporosis.

Conclusion

The prevalence of osteoporosis and osteopenia in patients with T2DM is high. Female gender, increasing age, normal BMI, low serum 25-hydroxyvitamin D, and pioglitazone use further increase the risk of osteoporosis.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    International Diabetes Federation. IDF Diabetic Atlas 7th Edition. http://www.idf.org/idf-diabetes-atlas-seventh-edition.

  2. 2.

    Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495–505.

  3. 3.

    Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res Off J Am Soc Bone Miner Res. 2009;24:702–9.

  4. 4.

    Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int. 2000;11:556–61.

  5. 5.

    Gulcelik NE, Bayraktar M, Caglar O, Alpaslan M, Karakaya J. Mortality after hip fracture in diabetic patients. Exp Clin Endocrinol Diabetes. 2011;119:414–8.

  6. 6.

    Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13:208–19.

  7. 7.

    Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91:3404–10.

  8. 8.

    Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27:319–32.

  9. 9.

    Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract. 1994;23:43–54.

  10. 10.

    Leidig-Bruckner G, Grobholz S, Bruckner T, Scheidt-Nave C, Nawroth P, Schneider JG. Prevalence and determinants of osteoporosis in patients with type 1 and type 2 diabetes mellitus. BMC Endocr Disord. 2014;14:33.

  11. 11.

    Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR–INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5:585–96.

  12. 12.

    Sharma B, Singh H, Chodhary P, Saran S, Mathur S. Osteoporosis in otherwise healthy patients with type 2 diabetes: a prospective gender based comparative study. Indian J Endocrinol Metab. 2017;21:535.

  13. 13.

    Prakash S, Jatti Ravi S, Ghagane SC, Jali SM, Jali MV. Prevalence of osteoporosis in type 2 diabetes mellitus patients using dual energy X-ray absorptiometry (DEXA) scan. Int J Osteoporos Metab Disord. 2017;10:10–6.

  14. 14.

    Mathen PG, Thabah MM, Zachariah B, Das AK. Decreased bone mineral density at the femoral neck and lumbar spine in South Indian patients with type 2 diabetes. J Clin Diagn Res JCDR. 2015;9:OC08–12.

  15. 15.

    Dutta M, Pakhetra R, Garg M. Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment. Med J Armed Forces India. 2012;68:48–52.

  16. 16.

    Rule AD. The CKD-EPI equation for estimating GFR from serum creatinine: real improvement or more of the same? Clin J Am Soc Nephrol. 2010;5:951–3.

  17. 17.

    Pal R, Bhadada SK, Singhare A, Bhansali A, Kamalanathan S, Chadha M, et al. Tumor-induced osteomalacia: experience from three tertiary care centers in India. Endocr Connect. 2019;8:266–76.

  18. 18.

    Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the nurses’ health study. Diabetes Care. 2006;29:1573–8.

  19. 19.

    Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18:427–44.

  20. 20.

    Napoli N, Strollo R, Paladini A, Briganti SI, Pozzilli P, Epstein S. The alliance of mesenchymal stem cells, bone, and diabetes. Int J Endocrinol. 2014;2014:690783.

  21. 21.

    Leslie WD, Aubry-Rozier B, Lamy O, Hans D. For the Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013;98:602–9.

  22. 22.

    Marwaha RK, Tandon N, Garg MK, Kanwar R, Narang A, Sastry A, et al. Bone health in healthy Indian population aged 50 years and above. Osteoporos Int. 2011;22:2829–36.

  23. 23.

    Wu S-F, Du X-J. Body mass index may positively correlate with bone mineral density of lumbar vertebra and femoral neck in postmenopausal females. Med Sci Monit. 2016;22:145–51.

  24. 24.

    Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, et al. Bone Mineral Density Changes during the Menopause Transition in a Multiethnic Cohort of Women. J Clin Endocrinol Metab. 2008;93:861-868.

  25. 25.

    Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353–73.

  26. 26.

    Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab. 2014;25:15–22.

  27. 27.

    Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes Endocrinol. 2018;6:847–58.

  28. 28.

    Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349–54.

  29. 29.

    Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized. Placebo-Controlled Trial J Clin Endocrinol Metab. 2008;93:1696–701.

  30. 30.

    Wan Y, Chong L-W, Evans RM. PPAR-γ regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496–503.

  31. 31.

    Jang M, Kim H, Lea S, Oh S, Kim JS, Oh B. Effect of duration of diabetes on bone mineral density : a population study on East Asian males. BMC Endocr Disord. 2018;18:61.

  32. 32.

    Majumdar SR, Leslie WD, Lix LM, Morin SN, Johansson H, Oden A, et al. Longer duration of diabetes strongly impacts fracture risk assessment: the Manitoba BMD cohort. J Clin Endocrinol Metab. 2016;101:4489–96.

  33. 33.

    Komatsu Y, Majima T. Negative correlation between BMD and HbA1C in patients with type 2 diabetes. Clin Calcium. 2006;16:1327–31.

Download references

Author information

Correspondence to Sanjay Kumar Bhadada.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study was approved by the Institute Ethical Committee, Post Graduate Institute of Medical Education and Research, Chandigarh, India (Reference number NK1739/MD 11259-60).

Informed consent

Informed consent was obtained from all the participants prior to enrollment.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aleti, S., Pal, R., Dutta, P. et al. Prevalence and predictors of osteopenia and osteoporosis in patients with type 2 diabetes mellitus: a cross-sectional study from a tertiary care institute in North India. Int J Diabetes Dev Ctries (2020). https://doi.org/10.1007/s13410-019-00786-3

Download citation

Keywords

  • Bone mineral density
  • Body mass index
  • Osteoporosis
  • Type 2 diabetes mellitus
  • Vitamin D
  • Pioglitazone